2cureX AB intends to carry out a directed issue of units

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.

2cureX AB (”2cureX” or the ”Company”) today announces its intention to carry out a directed issue of units of approximately SEK 30-40 million, consisting of two (2) shares and one (1) warrant of series TO1. The directed issue will be addressed to qualified investors through an accelerated book-building procedure, which commences after the publication of this press release. The Company will also, if the directed issue is completed, decide on the issuing of warrants of series TO1 that will be allotted to current shareholders.

2cureX intends to, with deviation from the shareholders’ preferential rights and with authorization from the extraordinary meeting held on July 2, 2020, implement a directed unit issue of SEK 30-40 million (the “Directed Issue”). One unit consists of two (2) shares and one (1) warrant of series TO1. 2cureX has engaged Mangold Fondkommission AB to investigate the conditions for the Directed Issue through a so-called accelerated book-building procedure.

The rationale for carrying out the Directed Issue and for the deviation from the shareholders’ preferential rights is to secure financing in a time- and cost-effective manner, and to diversify the shareholder base. The Company intends to use the proceeds from the Directed Issue to launch IndiTreat® in several markets. According to the board of directors, the Directed Issue will give 2cureX necessary capital to enable additional sales- and marketing activities of the Company’s product.

The subscription price and the number of units in the Directed issue are to be determined by the accelerated book-building procedure. The board of directors’ assessment is that the subscription price in the Directed Issue will be in accordance with market conditions since it will be determined through an accelerated book-building procedure.

If the Directed Issue is completed, the board of directors of 2cureX intends to decide on the issuing of warrants of series TO1 (same series as in the Directed Issue) which will be allotted to current shareholders in the Company. The warrants of series TO1 are intended to be admitted to trading on Nasdaq First North Growth Market.

The book-building procedure will begin no earlier than after the publication of this press release. Thereafter, the board of directors in the Company will decide on the Directed Issue and the allotment of units before the opening of Nasdaq First North Growth Market on July 7, 2020. Payment for units in the Directed Issue will be paid in cash.

The Directed Issue is subject to a resolution by the board of directors of 2cureX and can be cancelled at any time or be implemented with other terms than what is described above.

Advisers

Mangold Fondkommission AB is acting as sole bookrunner and financial adviser and Eversheds Sutherland Advokatbyrå AB is legal adviser in connection with the Directed Issue.

___________

Malmö in July 2020

2cureX AB

The Board of directors

N.B. This English text is an unofficial translation of the Swedish original of the press release, and in case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

For more information about 2cureX:

Ole Thastrup, Chief Executive Officer

E-mail: ot@2curex.com

Telephone: +45 22 11 53 99

www.2curex.com

This information is such that 2cureX AB is obliged to make public pursuant to the EU Market Abuse

Regulation. The information was submitted for publication, through the agency of the contact person set outabove, on July 6, 2020 at 17:31 CEST

Certified Adviser

Redeye AB

Telephone: +46 8 121 576 90

E-mail: certifiedadviser@redeye.se

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumors that are similar to the patient’s tumor and identifies the treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient can be offered the selected treatment.

IndiTreat® is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.

IndiTreat® is presently being introduced into the European market through an Early Access Program.

The aspiration is that IndiTreat® becomes a standard tool in Precision Medicine for cancer patients.

The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol: “2CUREX”).

Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in 2cureX in any jurisdiction, neither from 2cureX nor from someone else.

This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the 2cureX. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness. Mangold Fondkommission AB is acting for 2cureX in connection with the Directed Issue and no one else and will not be responsible to anyone other than 2cureX for providing the protections afforded to its clients nor for giving advice in relation to the Directed Share Issue or any other matter referred to herein.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States, Australia, Canada, New Zealand, Hong Kong, Japan, Singapore, South Africa, South Korea or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. 2cureX has not authorized any offer to the public of shares or rights in any member state of the EEA and no prospectus has been or will be prepared in connection with the Directed Issue. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation.

About Us

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients. IndiTreat® is currently being clinically validated in colorectal and ovarian cancer. The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).

Subscribe

Documents & Links